Chord Therapeutics, a Swiss developer of drugs for rare diseases, has raised $16 million in Series A financing. The investor was Omega Funds. In conjunction with the financing, Omega Funds’ Managing Director Claudio Nessi and Principal Francesco Draetta will join Chord Therapeutics’ board.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: